Big Pharma lends failed drugs to MRC reclamation project; Halozyme resumes a stalled cancer trial;

@FierceBiotech:  closes $500M venture fund, keeps late-stage focus. Report | Follow @FierceBiotech

@JohnCFierce: ICYMI - Puma shares triple on positive PhIII neratinib data, plans to file for approval. News | Follow @JohnCFierce

@DamianFierce: NIH funding for infectious disease research is on the rise. Brain disorders, not so much. More, via @EmilyMFierceFierceBiotech Research report | Follow @DamianFierce

@EmilyMFierce: Not good. Sierra Leone's chief Ebola doctor contracts the virus. More from Reuters | Follow @EmilyMFierce

> The U.K.'s Medical Research Council has convinced 7 drugmakers to hand over some once-failed compounds in hopes they can find new life in further study. The agreement involves AstraZeneca ($AZN), GlaxoSmithKline ($GSK), Johnson & Johnson ($JNJ), Eli Lilly ($LLY), Pfizer ($PFE), Takeda and UCB. More

> Halozyme ($HALO) has resumed patient enrollment in a Phase II study on the pancreatic cancer-treating PEGPH20 after the FDA removed a clinical hold. News

> Loxo Oncology has set terms for its planned $57 million IPO, expecting to offer 4.4 million shares at between $12 and $14 each, earmarking the potential proceeds for a Phase I treatment with potential in brain, lung, thyroid and breast cancers. Story

Medical Device News

@FierceMedDev: 3-D printing grows to scale within industry. Feature | Follow @FierceMedDev

@StacyALawrence: Smart bandage advances patient monitoring technology. Article | Follow @StacyALawrence

@VarunSaxena2: Frieden: stresses importance of stopping hospital-acquired infections. Sepsis, even Ebola, can be picked up at hospital. | Follow @VarunSaxena2

@MichaelGFierce: Most absorbent material on Earth gives poorly soluble drugs a boost. Story | Follow @MichaelGFierce

@EmilyWFierce: Power morcellator devices increase levels of undetected cancers in women, according to a new study. More | Follow @EmilyWFierce

> Catheters for deep vein thrombosis may do more harm than good. Story

> NeuroPace stimulator to be deployed in $40M DoD brain research initiative. More

> JAMA: Power morcellator devices increase levels of undetected cancers in women. Article

Pharma News

@FiercePharma: Best-read FP story Tuesday: News flash for biopharma bosses: More than half your employees want to leave. Article | Follow @FiercePharma

@TracyStaton: ICYMI: CVS Caremark lays out case for new specialty-drug pricing approach in JAMA editorial. More | Follow @TracyStaton

@EricPFierce: French animal health drugmaker Virbac sees US sales hurt by last year's recall of Iverhart Plus. Story from FierceAnimalHealth | Follow @EricPFierce

@CarlyHFierce: Brand websites drive new patients to scripts--and old patients to refills. FiercePharmaMarketing story | Follow @CarlyHFierce

> Biogen hikes its forecast as zippy Tecfidera fuels big profits. Story

> GSK slimming further as sales fall on Advair competition. More

> Judge refuses to toss off-label Revlimid marketing lawsuit against Celgene. Article

Drug Delivery News

> Most absorbent material on Earth gives poorly soluble drugs a boost. News

> Titan Phase III trial for subdermal implant begins enrollment. More

> MIT engineers discover key mechanism behind gold nanoparticle delivery. Article

> Galena Biopharma to market anti-vomit oral soluble film to cancer patients. Item

> Phase II trial kicks off for sublingually delivered Parkinson's therapy. Story

Diagnostics News

> AIDS 2014: Norway's Bionor produces possible biomarker to predict HIV vaccine effectiveness. Report

> PA startup's Series B will bring arthroscopic Dx needle through FDA clearance and launch. More

> GeneCentric grabs $5M Series A to advance testing for personalized cancer treatments. Story

> Quest forks over milestone payments to French Dx company in development deal. Article

> A missile, a plane crash and a profound loss to AIDS research. Editor's corner

Pharma Marketing News

> Pop some corks, Tecfidera sales folks: Your $700M for Q2 trounced estimates. More

> Brand websites drive new patients to scripts--and old patients to refills. Story

> Pfizer peddles advice for the lovelorn in Asia contraceptive campaign. Report

> Do teens hear what we hear? FDA aims to find out in study of acne, ADHD ads. Story

> FDA fast-tracks Roche's Avastin for tough-to-treat ovarian cancer. Article

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.